Explore the vast range of titles available.

Concentration data are reported for 18 trace elements in chalcopyrite from a suite of 53 samples from 15 different ore deposits obtained by laser-ablation inductively-coupled plasma-mass spectrometry. Chalcopyrite is demonstrated to host a wide range of trace elements including Mn, Co, Zn, Ga, Se, Ag, Cd, In, Sn, Sb, Hg, Tl, Pb and Bi. The concentration of some of these elements can be high (hundreds to thousands of ppm) but most are typically tens to hundreds of ppm. The ability of chalcopyrite to host trace elements generally increases in the absence of other co-crystallizing sulfides. In deposits in which the sulfide assemblage recrystallized during syn-metamorphic deformation, the concentrations of Sn and Ga in chalcopyrite will generally increase in the presence of co-recrystallizing sphalerite and/or galena, suggesting that chalcopyrite is the preferred host at higher temperatures and/or pressures. Trace-element concentrations in chalcopyrite typically show little variation at the sample scale, yet there is potential for significant variation between samples from any individual deposit. The Zn:Cd ratio in chalcopyrite shows some evidence of a systematic variation across the dataset, which depends, at least in part, on temperature of crystallization. Under constant physiochemical conditions the Cd:Zn ratios in co-crystallizing chalcopyrite and sphalerite are typically approximately equal. Any distinct difference in the Cd:Zn ratios in the two minerals, and/or a non-constant Cd:Zn ratio in chalcopyrite, may be an indication of varying physiochemical conditions during crystallization. Chalcopyrite is generally a poor host for most elements considered harmful or unwanted in the smelting of Cu, suggesting it is rarely a significant contributor to the overall content of such elements in copper concentrates. The exceptions are Se and Hg which may be sufficiently enriched in chalcopyrite to exceed statutory limits and thus incur monetary penalties from a smelter.

IntroductionSevere osteogenesis imperfecta (OI) is a debilitating disease with no cure or sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile, show promising effects and can form bone. The Boost Brittle Bones Before Birth (BOOSTB4) trial evaluates administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells) for OI type 3 or severe type 4.Methods and analysisBOOSTB4 is an exploratory, open-label, multiple dose, phase I/II clinical trial evaluating safety and efficacy of postnatal (n=15) or prenatal and postnatal (n=3, originally n=15) administration of BOOST cells for the treatment of severe OI compared with a combination of historical (1–5/subject) and untreated prospective controls (≤30). Infants<18 months of age (originally<12 months) and singleton pregnant women whose fetus has severe OI with confirmed glycine substitution in COL1A1 or COL1A2 can be included in the trial.Each subject receives four intravenous doses of 3×106/kg BOOST cells at 4 month intervals, with 48 (doses 1–2) or 24 (doses 3–4) hours in-patient follow-up, primary follow-up at 6 and 12 months after the last dose and long-term follow-up yearly until 10 years after the first dose. Prenatal subjects receive the first dose via ultrasound-guided injection into the umbilical vein within the fetal liver (16+0 to 35+6 weeks), and three doses postnatally.The primary outcome measures are safety and tolerability of repeated BOOST cell administration. The secondary outcome measures are number of fractures from baseline to primary and long-term follow-up, growth, change in bone mineral density, clinical OI status and biochemical bone turnover.Ethics and disseminationThe trial is approved by Competent Authorities in Sweden, the UK and the Netherlands (postnatal only). Results from the trial will be disseminated via CTIS, ClinicalTrials.gov and in scientific open-access scientific journals.Trial registration numbersEudraCT 2015-003699-60, EUCT: 2023-504593-38-00, NCT03706482.

3D Printing in Radiation Therapy provides practical and comprehensive guidance for the implementation, quality management, maintenance and safe use of a clinical 3D printing programme in the radiation therapy context. Radiation therapy is a safe and effective treatment that can benefit half of all cancer patients, and the introduction of an appropriately planned, managed, and resourced 3D printing programme can increase that benefit in terms of the radiation therapy patient experience, staff engagement, treatment accuracy and improved treatment outcomes, in addition to monetary savings. Part of IOP Series in Global Health and Radiation Oncology.

Failure of passive transfer of maternal immunity occurs in calves that fail to absorb sufficient immunoglobulins from ingested colostrum. The zinc sulphate turbidity test has been developed to test bovine neonates for this failure. The specificity of this test has been shown to be less than ideal. The objective was to examine how parameters of the zinc sulphate turbidity test may be manipulated in order to improve its diagnostic accuracy. One hundred and five blood samples were taken from calves of dairy cows receiving various rates of colostrum feeding. The zinc sulphate turbidity test was carried out multiple times on each sample, varying the solution strength, time of reaction and wavelength of light used and the results compared with those of a radial immunodiffusion test, which is the reference method for measuring immunoglobulin concentration in serum. Reducing the time over which the reaction occurs, or increasing the wavelength of light used to read the turbidity, resulted in decreased specificity without improving sensitivity. Increasing the concentration of the zinc sulphate solution used in the test was shown to improve the specificity without decreasing sensitivity. Examination of the cut-off points suggested that a lower cut-off point would improve the performance.

While the vaccination status of the older dog was unknown, the younger animal had been vaccinated against canine parainfluenza virus and Bordetella bronchiseptica (Nobivac KC), canine adenovirus 2 and canine distemper virus (Nobivac DHPPi). Characteristic gross and histopathological features of this disease were found on postmortem examination ( Priestnall and Erles 2011 ): there was extensive haemorrhage bilaterally within the pleural spaces and within consolidated lung extending into the caudal lobes. Histopathological examination of the lung revealed extensive severe obliteration of the alveolar architecture with flooding by a copious fibrinous exudate containing numerous admixed leucocytes, erythrocytes and varying numbers of Gram-positive cocci. The ST123 isolates associated with the 10-month-old greyhound that are reported here are also closely related to ST129, which was isolated from a septicaemic dog in the USA during 2005 and to another ST123 isolate SzBHS5, which was recovered from a case of acute fatal haemorrhagic pneumonia in dogs resident in a kennel in the London area in 1999 ( Webb and others 2008 ) ( Fig 1 ). Journal of Clinical Microbiology 50, 1355-1361 doi:10.1128/JCM.06094-11 PESAVENTO, P. A., HURLEY, K. F., BANNASCH, M. J., ARTIUSHIN, S. & TIMONEY, J. F. ( 2008 ) A clonal outbreak of acute fatal hemorrhagic pneumonia in intensively housed (shelter) dogs caused by Streptococcus equi subsp. zooepidemicus. Microbiology 154, 3016-3024 doi:10.1099/mic.0.2008/018911-0 WOOD, J. L. N., BURRELL, M. H., ROBERTS, C. A., CHANTER, N. & SHAW, Y. ( 1993 ) Streptococci and Pasteurella spp. associated with disease of the equine lower respiratory tract.

This study used automated data processing techniques to calculate a set of novel treatment plan accuracy metrics, and investigate their usefulness as predictors of quality assurance (QA) success and failure. A small sample of 151 beams from 23 prostate and cranial IMRT treatment plans were used in this study. These plans had been evaluated before treatment using measurements with a diode array system. The TADA software suite was adapted to allow automatic batch calculation of several proposed plan accuracy metrics, including mean field area, small-aperture, off-axis and closed-leaf factors. All of these results were compared to the gamma pass rates from the QA measurements and correlations were investigated. The mean field area factor provided a threshold field size (5 cm2, equivalent to a 2.2 × 2.2 cm2 square field), below which all beams failed the QA tests. The small aperture score provided a useful predictor of plan failure, when averaged over all beams, despite being weakly correlated with gamma pass rates for individual beams. By contrast, the closed leaf and off-axis factors provided information about the geometric arrangement of the beam segments but were not useful for distinguishing between plans that passed and failed QA. This study has provided some simple tests for plan accuracy, which may help minimise time spent on QA assessments of treatments that are unlikely to pass.

Patient specific applicators are needed for vaginal brachytherapy treatments in cases where conventional cylindrical applicators are unsuitable or unusable. These applicators are often produced using a time-consuming and comparatively imprecise moulding method. This proof-of-concept study used Monte Carlo calculations to investigate potential dosimetric effects from creating applicators using several common 3D printing materials. A sample mould was then replicated using a fused deposition modelling (FDM) technique, which allowed catheter channels to be precisely placed with reference to treatment goals, before 3D printing from thermoplastic using a consumer-grade 3D printer. The Monte Carlo results indicated that several FDM filaments caused substantial dose depletions (up to 6%) within the model applicators while having a minor effect (less than 1%) on dose in surrounding tissue. Compared to the sample mould, the 3D printed applicator achieved superior dosimetry in terms of target coverage, while also passing manual tests of smoothness and usability. This study demonstrated an overall process by which 3D printing could replace an imprecise and time-consuming manual process and potentially achieve improved dosimetry in brachytherapy treatments of irregular vaginal anatomy.

In this study, a 3D printing error inspired the development of a novel method for using a sagittally-sliced 3D printed thorax phantom to perform dosimetric verifications of lung radiotherapy treatment methods using a 2D ionization chamber array. A full-size thorax model was designed for 3D printing with multiple tissue densities including lung and bone and printed as a series of 2.4 cm sagittal slices using a Raise 3D Pro dual nozzle printer (Raise 3D Technologies Inc, Irvine, USA). An error introduced midway through printing resulted in one half of the phantom being printed at unrealistically high densities. A method was therefore devised whereby the entire phantom was used to plan two lung treatments, one conventionally fractionated and one hypo-fractionated, which were then verified via measurements using an Octavius 729 ionisation chamber array (PTW-Freiburg GmbH, Freiburg, Germany) in combination with several correctly-printed slices of the phantom. The measurements allowed dose distributions in planes through the target, adjacent to the target and at the location key of organs at risk to be verified, for both treatment plans. This method has the potential to be adapted for use with other phantoms and other dosimetry arrays to allow efficient evaluation of future treatment techniques.

Gamma evaluation is currently the most widely used dose comparison method for patient specific quality assurance (PSQA). However, existing methods for normalising the dose difference, using either the dose at the global maximum dose point or at each local point, can respectively lead to under- and over-sensitivity to dose differences in organ-at-risk structures. This may be of concern for plan evaluation from clinical perspectives. This study has explored and proposed a new method called structural gamma, which takes structural dose tolerances into consideration while performing gamma analysis for PSQA. As a demonstration of the structural gamma method, a total of 78 retrospective plans on four treatment sites were re-calculated on an in-house Monte Carlo system and compared with doses calculated from the treatment planning system. Structural gamma evaluations were performed using both QUANTEC dose tolerances and radiation oncologist specified dose tolerances, then compared with conventional global and local gamma evaluations. Results demonstrated that structural gamma evaluation is especially sensitive to errors in structures with restrictive dose constraints. The structural gamma map provides both geometric and dosimetric information on PSQA results, allowing straightforward clinical interpretation. The proposed structure-based gamma method accounts for dose tolerances for specific anatomical structures. This method can provide a clinically useful method to assess and communicate PSQA results, offering radiation oncologists a more intuitive way of examining agreement in surrounding critical normal structures.

3D printing is a promising solution for the production of bespoke phantoms and phantom components, for radiotherapy dosimetry and quality assurance (QA) purposes. This proof-of-concept study investigated the use of a dual-head printer to deposit two different filaments (polylactic acid (PLA) and StoneFil PLA-concrete (Formfutura BV, Nijmegen, Netherlands)) at several different in-fill densities, to achieve quasi-simultaneous 3D printing of muscle-, lung- and bone-equivalent media. A Raise 3D Pro 3D printer (Raise 3D Technologies Inc, Irvine, USA) was used to print one thoracic and one cranial phantom slab. Analysis using in-house 3D print QA software showed that the two humanoid phantom slabs geometrically matched the stereolithography (STL) files on which they were based, within 0.3 mm, except in one area of the thoracic slab that was affected by thermal warping by up to 3.4 mm. The 3D printed muscle, lung and bone materials in the two humanoid phantom slabs were approximately radiologically-equivalent to human muscle, lung and bone. In particular, the use of StoneFil with a nominally constant in-fill density of 100% resulted in regions that were approximately inner-bone-equivalent, at kV and MV energies. These regions were bounded by walls that were substantially denser than inner bone, although generally not dense enough to be truly cortical-bone-equivalent. This proof-of-concept study demonstrated a method by which multiple tissue-equivalent materials (eg. muscle-, lung- and bone-equivalent media) can be deposited within one 3D print, allowing complex phantom components to be fabricated efficiently in a clinical setting.